Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04084704
Other study ID # 7692
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date June 7, 2023

Study information

Verified date September 2023
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Osteoarthritis (OA) of the hip is one of the ten most disabling diseases in the developed world. Because OA gradually worsens over time, the sooner treatment is started, the more likely its impact is lessened. Hip OA is characterized by joint pain, cartilage degeneration, and an increase in disability. Multiple treatments are used to manage the degenerating hip as well as the associated pain. These include physiotherapy and rehabilitation, bracing, other walking aids, oral medications, injections, and in severe cases, surgery. Prior research has shown that injection of hyaluronic acid (HA) and corticosteroids can slow down OA degradation. This study will look at the effects of injecting Cingal into the hip, which expands on its current approved use in the treatment of knee OA.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 7, 2023
Est. primary completion date June 7, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: 1. Adult men or women ages 40 to 65 years 2. Hip OA (mild to moderate) diagnosed on x-ray and/or MRI (Tonnis grade 1 and 2) 3. Patient is using only nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen/ paracetamol (Tylenol) for pain relief during the month before receiving Cingal 4. Patient is willing to stop pain/anti-inflammatory medication at least two weeks prior to receiving Cingal through the end of the study (6 months) 5. Patient speaks, reads, and understands the language of the clinical site 6. Provision of informed consent Exclusion Criteria: 1. Evidence of hip dysplasia (centre edge angle less than 20 degrees) 2. Presence of advanced hip OA (Tonnis Grade 3) 3. Previous trauma to the affected hip requiring medical or surgical treatment 4. Previous surgery on the affected hip or contralateral hip 5. Severe acetabular deformities (e.g. acetabular protrusion, coxa profunda, circumferential labral ossification) 6. Infections or skin diseases at target hip joint 7. Immunosuppressive medication use 8. Chronic pain syndromes 9. Significant medical co-morbidities (requiring daily assistance for activities of daily living) 10. History of paediatric hip disease (e.g. Legg-Calve-Perthes; slipped capital femoral epiphysis) 11. Previous cartilage repair procedure (microfracture, Osteochondral Autograft Transplantation System (OATS) or Autologous Chondrocyte Implantation (ACI) with or without use of a scaffold (matrix) in the index hip) 12. Known hypersensitivity (allergy) to hyaluronan preparations 13. Known hypersensitivity (allergy) to triamcinolone hexacetonide preparations 14. Known sensitivity to any of the materials in Cingal 15. Patients with impaired cardio-renal function, endocrine, or other diseases or conditions that use of corticosteroid is warned 16. HA intra-articular injections into the index hip within the last 6 months before receiving Cingal 17. Corticosteroid therapy by systemic, intra-articular, or intramuscular route or oral corticosteroids within the last 6 months before receiving Cingal 18. Any injection received in the hip prior to receiving or received concurrently with Cingal 19. Uncontrolled diabetes 20. Subject is a woman who is pregnant or breastfeeding or a woman of child bearing potential who refuses to use effective contraception during the course of the study 21. Patient is incarcerated 22. Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities 23. Rheumatoid arthritis or gouty arthritis 24. Current diagnosis of osteomyelitis 25. Diagnosed musculoskeletal cancer or any diagnosed cancer, other than musculoskeletal if not on long term remission (e.g. at least 5 years or negative biopsy at last exam), except basal cell carcinoma 26. Patients who are at higher risk for post-surgical bleeding (e.g., bleeding disorder; taking anticoagulants except low dose aspirin or anti-platelet agents [e.g. ASA, Plavix]) or post-surgical infection (e.g., taking immunosuppressants; have a severe infection or a history of serious infection) 27. Participation in concurrent trial that involves a medical intervention 28. Patient is currently receiving workman's compensation or disability, has been involved in an motor vehicle accident, or is in litigation for workman's compensation or disability claims 29. Likely problems, in the judgment of the treating physician, with maintaining follow up (e.g. patients with no fixed address, plans to move out of town). This may include patients with severe mental disorders and drug addictions without adequate support.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cingal
Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.

Locations

Country Name City State
Canada McMaster University Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University Anika Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient reported hip pain as measured by Visual Analog Scale The primary objective of this observational study is to determine, among individuals with hip OA ages 40-65 years, the effect of Cingal on patient-reported hip pain, as measured by a Visual Analogue Scale (VAS), at 6-months post-injection. 6 months
Secondary Hip Function, as measured by the Hip Disability and Osteoarthritis Outcome Score (HOOS) The HOOS was designed to assess patient opinions about their hip and associated problems in an adult population with a hip disability with or without OA. The HOOS has been extensively validated and consists of 5 subscales for pain, other symptoms, function in activities of daily living, function in sports and recreation, and hip-related quality of life. 6 months
Secondary Health-related quality of life (HRQL) as measured by the Short Form-12 questionnaire (SF-12) The SF-12 may be self or interview-administered and can help document mental and physical components of quality of life. Points can range from 0-100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health. 6 months
Secondary Physical activity levels as measured by a wrist-worn activity tracker To be worn for one week prior to each follow-up visit. 6 months
Secondary Complications, including infection and other adverse events at 6-months post-injection. Adverse events 6 months
Secondary Range of motion ROM will be measured with standard anterior and posterior impingement tests, the log roll test, and hip flexion/extension, abduction/adduction, and internal/external rotation. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03326804 - H1 Hip Resurfacing Arthroplasty
Not yet recruiting NCT04257682 - Regional Anesthesia in Total Hip and Knee Arthroplasty Phase 4
Completed NCT02876120 - The STavanger osteoARThritis Study N/A
Terminated NCT02231567 - Neurocognitive Rehabilitation After Hip Replacement N/A
Recruiting NCT02174965 - Wear and Migration in the Corin Mini-Hip/Metafix and ECIMA Polyethylene N/A
Completed NCT01506024 - Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results N/A
Active, not recruiting NCT04070027 - Progressive Resistance Training Versus Total Hip Arthroplasty in Patients With Hip Osteoarthritis N/A
Withdrawn NCT04421196 - Opioid-free Total Hip Arthroplasty N/A
Not yet recruiting NCT05960903 - Patient Satisfaction After Primary THA In Assiut University
Not yet recruiting NCT04018690 - Project Arthritis Recovering Quality of Life Through Education - Hip N/A
Completed NCT03648060 - Efficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint Replacement N/A
Recruiting NCT05497349 - Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis N/A
Active, not recruiting NCT04879732 - RSA - ACTIS Hip Stem N/A
Active, not recruiting NCT05142462 - Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup
Recruiting NCT04665908 - PT-led Triage for Patients With Hip o Knee Osteoarthritis N/A
Completed NCT04648956 - Arabic Version of the ICOAP Questionnaire
Recruiting NCT05465096 - Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells. N/A
Completed NCT02884531 - Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial N/A
Completed NCT03031314 - Comparison of Knotless Barbed Suture and Standard Suture in Knee Replacement Patients N/A
Completed NCT03260309 - The Influence of Perioperative Optimisation to the Hip Arthroplasty Outcomes N/A